MRK · News · 20261102N

Keytruda Patent Expiration Outlook

Merck & Co., Inc. · 2026-11-02 · Importance 50 · Surprise 24

The report says Keytruda faces U.S. patent losses starting in 2028. Merck’s personalized cancer-vaccine collaboration with Moderna is presented as a potential response to that patent cliff. Overall-survival data and regulatory approval for the vaccine are still pending, and personalized manufacturing poses logistical challenges.

Key facts